DOCSLIB.ORG

Federal Register/Vol. 75, No. 123/Monday, June 28, 2010/Notices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 75, No. 123/Monday, June 28, 2010/Notices Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices 36681 DEPARTMENT OF JUSTICE Drug Schedule Drug Schedule Drug Enforcement Administration 1-phenylcyclohexylamine (7460) II 1-[1-(2- I Phencyclidine (7471). Thienyl)cyclohexyl]pyrrolidine Manufacturer of Controlled Phenylacetone (8501) .................. II (7473). Substances Notice of Application 1- II 1-Methyl-4-phenyl-4- I piperidinocyclohexanecarbonitri- propionoxypiperidine (9661). Pursuant to § 1301.33(a), Title 21 of le (8603). 1-(2-Phenylethyl)-4-phenyl-4- I the Code of Federal Regulations (CFR), Cocaine (9041) ............................. II acetoxypiperidine (9663). this is notice that on April 29, 2010, Codeine (9050) ............................. II 2,5-Dimethoxy-4-(n)- I Alltech Associates Inc., 2051 Waukegan Dihydrocodeine (9120) ................. II propylthiophenethylamine Road, Deerfield, Illinois 60015, made Ecgonine (9180) ........................... II (7348). application by renewal to the Drug Meperidine intermediate-B (9233) II 2,5-Dimethoxy-4- I Enforcement Administration (DEA) to Noroxymorphone (9668) .............. II ethylamphetamine (7399). 2,5-Dimethoxyamphetamine I be registered as a bulk manufacturer of (7396). the basic classes of controlled The company plans to manufacture 3,4,5-Trimethoxyamphetamine I substances listed in schedules I and II: high purity drug standards used for (7390). analytical application only in clinical, 3,4-Methylenedioxyamphetamine I Drug Schedule toxicological, and forensic laboratories. (7400). 3,4- I Methcathinone (1237) .................. I Any other such applicant, and any Methylenedioxymethamphetam- N-ethylamphetamine (1475) ......... I person who is presently registered with ine (7405). N,N-dimethylamphetamine (1480) I DEA to manufacture such substances, 3,4-Methylenedioxy-N- I 4-methylaminorex (cis isomer) I may file comments or objections to the ethylamphetamine (7404). (1590). issuance of the proposed registration 3-Methylfentanyl (9813) ................ I Alpha-ethyltryptamine (7249) ....... I pursuant to 21 CFR 1301.33(a). 3-Methylthiofentanyl (9833) .......... I Lysergic acid diethylamide (7315) I 4-Bromo-2,5- I 4-methylaminorex (cis isomer) I Any such comments or objections dimethoxyamphetamine (7391). (1590). should be addressed, in quintuplicate, 4-Bromo-2,5- I Alpha-ethyltryptamine (7249) ....... I to the Drug Enforcement dimethoxyphenethylamine Lysergic acid diethylamide (7315) I Administration, Office of Diversion (7392). 2,5-dimethoxy-4-(n)- I Control, Federal Register Representative 4-Methyl-2,5- I propylthiophenethylamine (ODL), 8701 Morrissette Drive, dimethoxyamphetamine (7395). (7348). Springfield, Virginia 22152; and must be 4-Methylaminorex (cis isomer) I Tetrahydrocannabinols (7370) ..... I (1590). Mescaline (7381) .......................... I filed no later than August 27, 2010. 4-Methoxyamphetamine (7411) ... I 4-bromo-2,5-dimethoxy-amphet- I Dated: June 17, 2010. 5-Methoxy-3,4- I amine (7391). Joseph T. Rannazzisi, methylenedioxyamphetamine 4–Bromo-2,5- I (7401). Deputy Assistant Administrator, Office of dimethoxyphenethylamine 5-Methoxy-N,N- I Diversion Control, Drug Enforcement (7392). diisopropyltryptamine (7439). Administration. 4-methyl-2,5-dimethoxy-amphet- I Acetorphine (9319) ....................... I amine (7395). [FR Doc. 2010–15517 Filed 6–25–10; 8:45 am] Acetyl-alpha-methylfentanyl I 2,5-dimethoxyamphetamine I BILLING CODE 4410–09–P (9815). (7396). Acetyldihydrocodeine (9051) ........ I 2,5-dimethoxy-4- I Acetylmethadol (9601) ................. I ethylamphetamine (7399). DEPARTMENT OF JUSTICE Allylprodine (9602) ....................... I 3,4-methylenedioxy amphetamine I Alphacetylmethadol except levo- I (7400). Drug Enforcement Administration alphacetylmethadol (9603). N-hydroxy-3,4- I Alpha-ethyltryptamine (7249) ....... I methylenedioxyamphetamine Importer of Controlled Substances; Alphameprodine (9604) ................ I (7402). Notice of Application Alphamethadol (9605) .................. I 3,4-methylenedioxy-N- I Alpha-methylfentanyl (9814) ........ I ethylamphetamine (7404). Alpha-methylthiofentanyl (9832) ... I 3,4- I Pursuant to Title 21 Code of Federal Alpha-methyltryptamine (7432) .... I methylenedioxymethamphetam- Regulations 1301.34(a), this is notice Aminorex (1585) ........................... I ine (MDMA) (7405). that on April 27, 2010, Research Benzethidine (9606) ..................... I 4-methoxyamphetamine (7411) ... I Triangle Institute, Kenneth H. Davis Jr., Benzylmorphine (9052) ................ I Alpha-methyltryptamine (7432) .... I Hermann Building, East Institute Drive, Betacetylmethadol (9607) ............ I Bufotenine (7433) ......................... I P.O. Box 12194, Research Triangle, Beta-hydroxy-3-methylfentanyl I Diethyltryptamine (7434) .............. I North Carolina 27709, made application (9831). Dimethyltryptamine (7435) ........... I by renewal to the Drug Enforcement Beta-hydroxyfentanyl (9830) ........ I Psilocybin (7437) .......................... I Administration (DEA) for registration as Betameprodine (9608) .................. I Psilocyn (7438) ............................. I Betamethadol (9609) .................... I 5-methoxy-N,N- I an importer of the basic classes of Betaprodine (9611) ....................... I diisopropyltryptamine (7439). controlled substances listed in Bufotenine (7433) ......................... I N-ethyl-1-phenylcyclohexylamine I schedules I and II: Cathinone (1235) .......................... I (7455). Clonitazene (9612) ....................... I 1-(1-phenylcyclohexyl)-pyrrolidine I Drug Schedule Codeine methylbromide (9070) .... I (7458). Codeine-N-Oxide (9053) .............. I 1-[1-(2-thienyl)-cyclohexyl]-piper- I 1-(1-Phenylcyclohexyl)pyrrolidine I Cyprenorphine (9054) .................. I idine (7470). (7458). Desomorphine (9055) ................... I Dihydromorphine (9145) ............... I 1-[1-(2- I Dextromoramide (9613) ............... I Normorphine (9313) ..................... I Thienyl)cyclohexyl]piperidine Diampromide (9615) ..................... I Methamphetamine (1105) ............ II (7470). Diethylthiambutene (9616) ........... I VerDate Mar<15>2010 21:02 Jun 25, 2010 Jkt 220001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\28JNN1.SGM 28JNN1 jlentini on DSKJ8SOYB1PROD with NOTICES 36682 Federal Register / Vol. 75, No. 123 / Monday, June 28, 2010 / Notices Drug Schedule Drug Schedule Drug Abuse (NIDA) for research activities. Diethyltryptamine (7434) .............. I Psilocyn (7438) ............................. I Difenoxin (9168) ........................... I Racemoramide (9645) .................. I No comments, objections, or requests Dihydromorphine (9145) ............... I Tetrahydrocannabinols (7370) ..... I for any hearings will be accepted on any Dimenoxadol (9617) ..................... I Thebacon (9315) .......................... I application for registration or re- Dimepheptanol (9618) .................. I Thiofentanyl (9835) ...................... I registration to import crude opium, Dimethylthiambutene (9619) ........ I Tilidine (9750) ............................... I poppy straw, concentrate of poppy Dimethyltryptamine (7435) ........... I Trimeperidine (9646) .................... I straw, and coca leaves. As explained in Dioxaphetyl butyrate (9621) ......... I 1-Phenylcyclohexylamine (7460) II Dipipanone (9622) ........................ I 1- II the Correction to Notice of Application Drotebanol (9335) ........................ I Piperidinocyclohexanecarbonitr- pertaining to Rhodes Technologies, 72 Ethylmethylthiambutene (9623) .... I ile (8603). FR 3417 (2007), comments and requests Etonitazene (9624) ....................... I Alfentanil (9737) ........................... II for hearings on applications to import Etorphine except HCl (9056) ........ I Alphaprodine (9010) ..................... II narcotic raw material are not Etoxeridine (9625) ........................ I Amobarbital (2125) ....................... II appropriate. Fenethylline (1503) ....................... I Amphetamine (1100) .................... II Furethidine (9626) ........................ I Anileridine (9020) ......................... II Any bulk manufacturer who is Gamma Hydroxybutyric Acid I Bezitramide (9800) ....................... II presently, or is applying to be, (2010). Carfentanil (9743) ......................... II registered with DEA to manufacture Heroin (9200) ............................... I Coca Leaves (9040) ..................... II such basic classes of controlled Hydromorphinol (9301) ................. I Cocaine (9041) ............................. II Hydroxypethidine (9627) .............. I Codeine (9050) ............................. II substances listed in schedule I or II, Ibogaine (7260) ............................ I Dextropropoxyphene, bulk (non- II which fall under the authority of section Ketobemidone (9628) ................... I dosage forms) (9273). 1002(a)(2)(B) of the Act (21 U.S.C. 952 Levomoramide (9629) .................. I Dihydrocodeine (9120) ................. II (a)(2)(B)) may, in the circumstances set Levophenacylmorphan (9631) ...... I Dihydroetorphine (9334) ............... II forth in 21 U.S.C. 958(i), file comments Lysergic acid diethylamide (7315) I Diphenoxylate (9170) ................... II or objections to the issuance of the Marihuana (7360) ......................... I Ethylmorphine (9190) ................... II Mecloqualone (2572) .................... I Etorphine HCl (9059) ................... II proposed registration, and may, at the Mescaline
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Federal Register/Vol. 70, No. 42/Friday, March 4, 2005
    Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices 10677 Drug Schedule Drug Schedule Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, Cathinone (1235) .......................... I Alpha-Methylfentanyl (9814) ........ I the above named company is granted Methcathinone (1237) .................. I Acetyl-alpha-methylfentanyl I registration as a bulk manufacturer of N-Ethylamphetamine (1475) ........ I (9815). the basic classes of controlled N,N-Dimethylamphetamine (1480) I Beta-hydroxyfentanyl (9830) ........ I substances listed. Aminorex (1585) ........................... I Beta-hydroxy-3-methylfentanyl I 4-7Methylaminorex (cis isomer) I (9831). Dated: Febuary 22, 2005. (1590). Alpha-Methylthiofentanyl (9832) ... I William J. Walker, Gamma hydroxybutyric acid I 3–Methylthiofentanyl (9833) ......... I Deputy Assistant Administrator, Office of Thiofentanyl (9835) ...................... I (2010). Diversion Control, Drug Enforcement Amphetamine (1100) .................... II Methaqualone (2565) ................... I Administration. Alpha-Ethyltryptamine (7249) ....... I Methamphetamine (1105) ............ II Lysergic acid diethylamide (7315) I Phenmetrazine (1631) .................. II [FR Doc. 05–4205 Filed 3–3–05; 8:45 am] Tetrahydrocannabinols (7370) ..... I Methylphenidate (1724) ................ II BILLING CODE 4410–09–P Mescaline (7381) .......................... I Ambobarbital (2125) ..................... II 3,4,5-Trimethoxyamphetamine I Pentobarbital (2270) ..................... II (7390).
    [Show full text]
  • SENATE BILL No. 259 No
    SENATE BILL No. 259 SENATE BILL No. 259 March 10, 2011, Introduced by Senators JONES, CASPERSON and SCHUITMAKER and referred to the Committee on Judiciary. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7212 (MCL 333.7212), as amended by 2010 PA 171. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7212. (1) The following controlled substances are 2 included in schedule 1: 3 (a) Any of the following opiates, including their isomers, 4 esters, the ethers, salts, and salts of isomers, esters, and 5 ethers, unless specifically excepted, when the existence of these 6 isomers, esters, ethers, and salts is possible within the 7 specific chemical designation: SENATE BILL No. 259 00981'11 TLG 2 1 Acetylmethadol Difenoxin Noracymethadol 2 Allylprodine Dimenoxadol Norlevorphanol 3 Alpha-acetylmethadol Dimepheptanol Normethadone 4 Alphameprodine Dimethylthiambutene Norpipanone 5 Alphamethadol Dioxaphetyl butyrate Phenadoxone 6 Benzethidine Dipipanone Phenampromide 7 Betacetylmethadol Ethylmethylthiambutene Phenomorphan 8 Betameprodine Etonitazene Phenoperidine 9 Betamethadol Etoxeridine Piritramide 10 Betaprodine Furethidine Proheptazine 11 Clonitazene Hydroxypethidine Properidine 12 Dextromoramide Ketobemidone Propiram 13 Diampromide Levomoramide Racemoramide 14 Diethylthiambutene Levophenacylmorphan Trimeperidine 15 Morpheridine 16 (b) Any of the following opium derivatives, their salts, 17 isomers, and salts of isomers, unless specifically excepted, when 18 the existence of these salts, isomers, and salts of
    [Show full text]
  • 3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MEMANTINE and DONEPEZIL ---------------------CONTRAINDICATIONS -------------------- HYDROCHLORIDES EXTENDED-RELEASE Memantine and donepezil hydrochlorides extended-release CAPSULES safely and effectively. See full prescribing capsules are contraindicated in patients with known information for MEMANTINE and DONEPEZIL hypersensitivity to memantine hydrochloride, donepezil HYDROCHLORIDES EXTENDED-RELEASE hydrochloride, piperidine derivatives, or to any excipients CAPSULES. used in the formulation. (4) MEMANTINE and DONEPEZIL HYDROCHLORIDES ------------------WARNINGS AND PRECAUTIONS ---------- extended-release capsules, for oral use • Memantine and donepezil hydrochlorides extended- Initial U.S. Approval: 2014 release is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. (5.1) ------------------RECENT MAJOR CHANGES ----------------- • Memantine and donepezil hydrochlorides extended- Indications and Usage (1) 07/2016 release may have vagotonic effects on the sinoatrial and Dosage and Administration (2.1, 2.3) 07/2016 atrioventricular nodes manifesting as bradycardia or heart block. (5.2) ------------------INDICATIONS AND USAGE------------------ • Monitor patients for symptoms of active or occult Memantine and donepezil hydrochlorides extended-release gastrointestinal bleeding, especially those at increased capsules are a combination of memantine hydrochloride, an risk for developing ulcers. (5.3) NMDA receptor
    [Show full text]
  • Temporary Class Drug Order Report: 5-6APB and Nbome Compounds
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives.
    [Show full text]
  • LSD), Which Produces Illicit Market in the USA
    DEPENDENCE LIABILITY OF "NON-NARCOTIC 9 DRUGS 81 INDOLES The prototype drug in this subgroup (Table XVI) potentials. Ibogaine (S 212) has appeared in the is compound S 219, lysergide (LSD), which produces illicit market in the USA. dependence of the hallucinogen (LSD) type (see above). A tremendous literature on LSD exists which documents fully the dangers of abuse, which REFERENCES is now widespread in the USA, Canada, the United 304. Sandoz Pharmaceuticals Bibliography on Psychoto- Kingdom, Australia and many western European mimetics (1943-1966). Reprinted by the US countries (for references see Table XVI). LSD must Department of Health, Education, & Welfare, be judged as a very dangerous substance which has National Institute of Mental Health, Washington, no established therapeutic use. D.C. 305. Cerletti, A. (1958) In: Heim, R. & Wasson, G. R., Substances S 200-S 203, S 206, S 208, S 213-S 218 ed., Les champignons hallucinogenes du Mexique, and S 220-S 222 are isomers or congeners of LSD. pp. 268-271, Museum national d'Histoire natu- A number of these are much less potent than LSD in relle, Paris (Etude pharmacologique de la hallucinogenic effect or are not hallucinogenic at all psilocybine) (compounds S 203, S 213, S 216, S 217, S 220 and 306. Cohen, S. (1965) The beyond within. The LSD S 222) and accordingly carry a lesser degree of risk story. Atheneum, New York than LSD. None of these weak hallucinogens has 307. Cohen, S. & Ditman, K. S. (1963) Arch. gen. been abused. Other compounds are all sufficiently Psychiat., 8, 475 (Prolonged adverse reactions to potent to make it likely that they would be abused if lysergic acid diethylamide) 308.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]